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AdvocacyTuberculosis (TB) is now the single biggest infectious disease
killer in the world, surpassing malaria and HIV/AIDS. In 2014, there
were an estimated 9.6 million incident TB cases and 1.5 million
deaths.1 It is not widely appreciated that TB is also a major cause of
disease and death in young children.2,3 New estimates from the
World Health Organization (WHO) are that 1 million children
developed TB during 2014.1 This is disconcerting because children
have poor access to TB services in most resource-limited settings
and paediatric cases provide an accurate reﬂection of uncontrolled
TB transmission within communities. Although the cost-effective
DOTS strategy helped to bring the global tuberculosis (TB)
epidemic under control in many parts of the world, progress has
been limited in areas affected by poverty, war and rising rates of
drug resistant TB.4,5
The emergence and spread of multi-drug resistant (MDR)-TB
pose a major threat to recent gains.4,5 It is estimated that nearly
half a million (480 000) MDR-TB cases occurred in 2014;
accounting for 3.3% of new and 20% of re-treatment TB cases.1
The highest MDR-TB case-loads exist in the Indian subcontinent,
China, the Russian Federation and Southern Africa.1 For many years
the epidemic potential of transmitted MDR-TB was ignored and the
dogma that most MDR-TB cases acquire drug-resistance because of
poor treatment adherence became ﬁrmly entrenched. The
perception that drug resistant strains have reduced ‘‘ﬁtness’’
and are unlikely to be transmitted had a major inﬂuence on TB
control policy. It motivated a renewed focus on basic DOTS to stop
the generation of MDR-TB cases; ‘‘turning off the tap’’ was
considered an adequate public health response.
The relative over-representation of MDR-TB among re-treat-
ment cases is often used to support this dogma; although the
majority of MDR–TB cases are now diagnosed among new cases.1
Recent modelling data suggest that even among MDR-TB cases
diagnosed at re-treatment, the majority represent transmitted (not
acquired) MDR-TB disease.6 The description of multiple well-
deﬁned clonal MDR-TB outbreaks provides genotypic evidence of
epidemic spread,7,8 as does the fact that 60% of Mongolian TB
patients in whom ﬁrst-line treatment failed were resistant to
streptomycin; a drug to which they have never been exposed
before.9 The high number of children with MDR-TB and the facthttp://dx.doi.org/10.1016/j.ijid.2016.03.015
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cases provide epidemiological proof of MDR-TB transmission
within households and communities.2,10 A recent analysis of
100 paediatric specimens held in the strain library of the Chinese
Centre for Disease Control and Prevention demonstrated high rates
of drug-resistance; any drug resistance in 55% and MDR in 22%.11
It is important to ensure optimal basic TB program performance
and to limit the generation of newly acquired drug resistance.
However, if TB treatment and prevention programs focus
exclusively on drug susceptible disease, uncontrolled MDR-TB
transmission could lead to future epidemic replacement, where
MDR-TB strains become more prevalent than drug-susceptible
strains. The possibility of epidemic replacement is illustrated by
parts of the Russian Federation where over 30% of newly diagnosed
cases have MDR-TB.3 Sub-Saharan Africa represents the epicentre
of human immunodeﬁciency virus (HIV) and TB co-infection.
Swaziland report TB/HIV co-infection rates exceeding 80%, with
high rates of MDR-TB among co-infected patients.12 Since delayed
MDR-TB diagnosis might facilitate transmission among immune
compromised patients, the occurrence of an rpoB Ile491Phe
mutation that is not detected by the Xpert MTB/RIF1 assay is
particularly problematic.12
High and rising rates of MDR-TB have relevance beyond the
worst affected areas, since TB does not respect national borders.
People are highly mobile and their mobility underpins global
economic activity. Large scale population movements are also
triggered by war and famine, with appeals for safe refuge.
Interventions to screen for active TB and latent M. tuberculosis
infection are compromised if prophylactic treatment options are
ineffective in those harbouring MDR-TB strains. Current diagnostic
tests are unable to identify latent infection with an MDR strain, or
to detect a re-infection event after previous preventive therapy or
TB treatment. There is an urgent need for improved epidemiologi-
cal understanding of MDR-TB spread, guided by a better
description of the evolution and transmission dynamics of drug-
resistant M. tuberculosis strains.
1. The new ‘‘End TB strategy’’
The World Health Assembly approved the new End TB Strategy
in May 2014.13 The End TB Strategy includes ambitious targets to
reduce TB deaths by 95% and cut new cases by 90% from 2015 to
2035, and to ensure that no family is burdened with catastrophic
expenses due to TB. It calls on all governments to demonstrate
high-level political commitment by prioritizing efforts to end TB,
backed by adequate resource allocation and inclusion of the mostciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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strategy’’ is to reduce global disease burdens, with the greatest
gains to be made in high burden countries. The strategy does not
include speciﬁc targets for low burden countries apart from
encouragement to aim for TB pre-elimination, deﬁned as an annual
TB incidence of less than 1 case/100 000 population. The reality in
most low burden countries is that TB is essentially an imported
disease with minimal local transmission. Given its limited health
impact, compared to things like obesity, diabetes and cardiovas-
cular disease or cancer, it is difﬁcult to maintain high-level
engagement and justify continued domestic investment in TB
control efforts. A new paradigm is required to engage low TB
burden countries and add momentum to global TB control efforts.
2. Engaging low burden countries
A potential mechanism to encourage continued TB invest-
ment in low-burden countries is to create a pathway for formal
recognition as being ‘‘TB transmission free’’. Achieving and
maintaining a ‘‘TB transmission free’’ status could provide
strong impetus for regional action in low burden areas, similar
to the focus provided by the ‘‘Roll back Polio’’ campaign.14
Challenging low burden countries to aspire to this goal may
galvanize national action and encourage the incorporation of
cutting-edge molecular tools into routine TB control activities,
together with the development of active response systems.
Beneﬁts of rapid advances in pathogen genomics and whole
genome sequencing include simultaneous detection of drug-
resistance mutations (allowing for earlier initiation of effective
medications, thereby cutting transmission) and accurate identi-
ﬁcation of transmission clusters to guide outbreak investigation.
It will allow TB control efforts to be at the forefront of the
‘‘genomic revolution’’, linking sophisticated strain and drug-
resistance mutation analysis to enhanced patient care and better
targeted public health responses.15,16
A policy of TB elimination that focuses exclusively on absolute
case numbers, as deﬁned in the WHO ‘‘Framework for TB
elimination in low-incidence countries’’,17 raises practical and
ethical challenges. Increasing the intensity and scope of screening
programs for latent TB infection (LTBI) is clearly important as part
of an overall TB elimination strategy, given the long latency periods
experienced by some TB patients.18 However, careful consider-
ation should be given to the strategies required to ensure safe and
efﬁcient implementation.18,19 Managing LTBI in vulnerable and
disadvantaged groups will require new ways of working with local
communities, social welfare organisations, and government
departments. No comprehensive analysis has been undertaken
to explore the ethical, economic and social impacts of a policy shift
towards TB elimination, intending to eliminate the ‘‘pool of latent
infection’’ from which future cases may arise. Given high
population mobility and signiﬁcant re-infection risk, eradicating
the ‘‘pool of latent infection’’ is not a feasible aim. Careful
consideration should be given to the risk:beneﬁt ratio of
preventive therapy in individual patients, with clear beneﬁt in
young children and immune compromised patients.20 However,
there is a difﬁcult ethical tension between the interests of low risk
individuals with LTBI, who stand to beneﬁt very little from
preventive therapy, and potential societal beneﬁts if the ‘‘pool of
latent infection’’ is reduced. In ‘‘TB transmission free’’ settings,
where local transmission is limited to an absolute minimum (<1
case of locally transmitted TB/100 000 population), the societal
beneﬁt derived from the LTBI treatment is minimal and ethically
the patient’s best interest becomes the sole determining factor.
This provides additional motivation for countries to strive towards
‘‘TB transmission free’’ status.3. Engaging high burden settings
The stigma associated with TB, at the individual and community
levels, is well characterized and presents a major hurdle to TB
control activities in many high burden settings.20 However, an
issue that is less often discussed or studied is the political stigma
associated with TB.21 Politicians in countries with rapidly growing
economies aspire to be seen as progressive and making a
contribution to rid their country of the ‘‘shackles of poverty’’.
Given TB’s intimate association with poverty and deprivation there
is reluctance to acknowledge the full extent of the TB disease
burden, especially in settings where this remains stubbornly high.
This may explain some of the discrepancies observed between
notiﬁed cases, disease burden estimates and actual prevalence
surveys. Re-assessment of Indonesia’s estimated TB incidence,
after a recent prevalence survey detected double the number of
case expected, now places Indonesia ahead of China as the country
with the second highest number of TB cases, surpassed only by
India.1 Issues related to political stigma are compounded by rising
rates of MDR-TB in many Asian countries, with pressure on TB
control programmes to ‘‘solve the problem’’, despite inadequate
resource allocation.
Due to rapid economic growth many countries that were
previously supported by the Global Fund no longer qualify. It is
imperative that the Global Fund establishes a clear transition
pathway to secure domestic funding streams (or other support
mechanisms) that can sustain MDR-TB treatment programmes
and prevent a recurrence of the setbacks suffered by MDR-TB
treatment programmes in China when Global Fund support
ended in 2015. Increased domestic resources could be secured
through innovative health ﬁnancing mechanisms, such as
universal health insurance and social protection schemes.
However, low income countries will continue to require external
donor support. Major funding shortfalls demonstrate the need for
greatly increased advocacy and strong regional political com-
mitment. Innovative regional funding mechanisms should be
explored that are dynamic and responsive to local circumstances,
especially in the Asia-Paciﬁc where economic growth has been
strong and contributions to traditional funding mechanisms
limited.21
Dr. Margaret Chan, Director General of the WHO, made the
following call when announcing the ambitious End TB strategy 13:
‘‘Everyone with TB should have access to the innovative tools and
services they need for rapid diagnosis, treatment and care. This is a
matter of social justice, fundamental to our goal of universal health
coverage. Given the prevalence of drug-resistant tuberculosis,
ensuring high quality and complete care will also beneﬁt global
health security. I call for intensiﬁed global solidarity and action to
ensure the success of this transformative End TB Strategy.’’ The real
challenge is identifying the international ‘‘levers’’ that can
translate these worthy ambitions into concerted action with
strong contributions from high and low burden countries.
Conﬂicts of interests: Authors declare no conﬂicts of interest.
References
1. Global Tuberculosis Report 2015. World Health Organisation, Geneva 2015.
2. Jenkins HE, Tolman AW, Yuen CM, Parr JB, Keshavjee S, Pe´rez-Ve´lez CM, et al.
Incidence of multidrug-resistant tuberculosis disease in children: systematic
review and global estimates. Lancet 2014;383:1572–9.
3. Graham S, Sismandis C, Menzies HJ, Marais BJ, Detjen AK, Black RE. Importance
of tuberculosis to address child survival. Lancet 2014;383:1605–7.
4. Raviglione M, Marais B, Floyd K, Lo¨nnroth K, Getahun H, Migliori GB, et al.
Scaling up of interventions to achieve global tuberculosis control: progress, new
developments and update. Lancet 2012;379:1902–13.
5. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, et al. Drug-
resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis
2013;13:529–39.
Editorial / International Journal of Infectious Diseases 45 (2016) 100–1021026. Kendall EA, Fofana MO, Dowdy DW. L Burden of transmitted multidrug resis-
tance in epidemics of tuberculosis: a transmission modelling analysis. Lancet
Respir Med 2015;3:963–72.
7. Marais BJ, Mlambo CK, Rastogi N, Zozzio T, Duse A, Victor TC, et al. Epidemic
spread of multidrug-resistant (MDR) tuberculosis in Johannesburg, South
Africa. J Clin Microbiol 2013;51:1818–25.
8. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I,
et al. Evolution and transmission of drug-resistant tuberculosis in a Russian
population. Nat Genet 2014;46:279–86.
9. Dobler CC, Korver S, Batbayar O, Nyamdulam B, Oyuntsetseg S, Tsolmon B, et al.
Multidrug-resistant tuberculosis among ﬁrst-line treatment failures in
Mongolia. Emerg Infect Dis 2015;21:1451–4.
10. Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR. Surveillance of
antituberculosis drug resistance amongst children from the Western Cape
Province of South Africa – an upward trend. Am J Public Health 2009;99:
1486–90.
11. Jiao WW, Liu ZG, Han R, Zhao XQ, Dong F, Dong HY, et al. Prevalence of drug
resistant Mycobacterium tuberculosis among children in China. Tuberculosis
2015;95(95):315–20.
12. Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P, et al.
Detection of drug-resistant tuberculosis by Xpert MRB/RIF in Swaziland. N Engl J
Med 2015;372:1181–2.
13. WHO 2014. End TB Strategy. http://www.who.int/tb/End_TB_brochure.pdf -
accessed February 24th 2016.
14. Marais BJ, Tadolini M, Zignol M, Migliori GB. Paediatric TB – lessons from
Denmark and inclusive strategies to consider. Eur Resp J 2014;43:678–84.
15. Outhred AC, Jelfs P, Suliman B, Hill-Cawthorne GA, Crawford AB, Marais BJ, et al.
Added value of whole genome sequencing for management of highly drug
resistant tuberculosis. J Antimicrob Chemother 2015;70:1198–202.
16. Outhred AC, Holmes N, Sadsad R, Martinez E, Jelfs P, Hill-Cawthorne GA, et al.
Identifying Likely Transmission Pathways within a 10-Year Community Out-
break of Tuberculosis by High-Depth Whole Genome Sequencing. PLoS One
2016;11(3):e0150550.
17. WHO 2014. Towards TB elimination: an action framework for low incidence
countries. http://apps.who.int/iris/bitstream/10665/132231/1/9789241507707_
eng.pdf - accessed February 24th 2016.
18. Rangaka MX, Cavalcante SC, Marais BJ, Thim S, Martinson NA, Swaminathan S,
et al. Controlling the Seedbeds of Tuberculosis: Diagnosis and Treatment of
Tuberculosis Infection. Lancet 2015;386:2344–53.19. Hill PC, Dye C, Viney K, Tabutoa K, Bissell K, Williams BG, et al. Mass treatment
to eliminate tuberculosis – a neglected strategy. Int J Tuberc Lung Dis
2014;18:899–904.
20. Murray E, Bond V, Marais BJ, Godfrey-Faussett P, Ayles H, Beyers N. High levels
of vulnerability and anticipated stigma reduce the impetus for tuberculosis
diagnosis in Cape Town, South Africa. Health Policy Plan 2013;28:410–8.
21. Islam T, Marais BJ, Nhung NV, Chiang C-Y, Yew WW, Yoshiyama T, et al. Western
Paciﬁc Regional Green Light Committee: progress and way forward. Int J Infect
Dis 2015;32:161–5.
B.J. Maraisa,*
A.C. Outhreda
A. Zumlab
aThe Marie Bashir Institute for Infectious Diseases and Biosecurity
(MBI) and Centre for Research Excellence in Tuberculosis (TB-CRE),
University of Sydney, Australia
bCenter for Clinical Microbiology, Division of Infection and Immunity,
University College London and NIHR Biomedical Research Centre,
UCL Hospitals NHS Foundation Trust, London, United Kingdom
*Corresponding author. Centre for Research Excellence in
Tuberculosis (TB-CRE), Sydney Medical School,
University of Sydney, Australia.
E-mail address: ben.marais@health.nsw.gov.au (B.J. Marais).
Corresponding Editor: Eskild Petersen, Aarhus, Denmark.
15 March 2016
Accepted 15 March 2016
